Unknown

Dataset Information

0

A Phase 2, Double-Blind, Placebo-Controlled Randomized Trial Assessing the Efficacy of ABT-436, a Novel V1b Receptor Antagonist, for Alcohol Dependence.


ABSTRACT: Alcohol use disorder has been linked to dysregulation of the brain stress systems, producing a negative emotional state leading to chronic relapsing behavior. Vasopressin receptors appear to have a regulatory role in stress, anxiety, and alcohol. This study evaluated the novel compound, ABT-436, a V1b receptor antagonist, in alcohol-dependent participants in a 12-week clinical trial. Men and women (n=150) who met criteria for DSM-IV alcohol dependence were recruited across four sites. Participants received double-blind ABT-436 or placebo, and a computerized behavioral intervention. ABT-436 was titrated to 800?mg/day during weeks 2-12. Although the primary outcome, percentage of heavy drinking days, was lower in participants receiving ABT-436 compared with placebo, this difference was not statistically significant (31.3 vs 37.6, respectively; p=0.172; d=0.20). However, participants receiving ABT-436 had significantly greater percentage of days abstinent than those receiving placebo (51.2 vs 41.6, respectively; p=0.037; d=0.31). No significant differences were found between treatment groups on any other measures of drinking, alcohol craving, or alcohol-related consequences. Smokers receiving ABT-436 smoked significantly fewer cigarettes per week than those receiving placebo (p=0.046). ABT-436 was well tolerated, with diarrhea (mild-to-moderate severity) being the most common side effect. In subgroup analyses, participants with relatively higher baseline levels of stress responded better to ABT-436 than placebo on select drinking outcomes, suggesting there may be value in testing medications targeting the vasopressin receptor in high stress, alcohol-dependent patients.

SUBMITTER: Ryan ML 

PROVIDER: S-EPMC5506792 | biostudies-literature | 2017 Apr

REPOSITORIES: biostudies-literature

altmetric image

Publications

A Phase 2, Double-Blind, Placebo-Controlled Randomized Trial Assessing the Efficacy of ABT-436, a Novel V1b Receptor Antagonist, for Alcohol Dependence.

Ryan Megan L ML   Falk Daniel E DE   Fertig Joanne B JB   Rendenbach-Mueller Beatrice B   Katz David A DA   Tracy Katherine A KA   Strain Eric C EC   Dunn Kelly E KE   Kampman Kyle K   Mahoney Elizabeth E   Ciraulo Domenic A DA   Sickles-Colaneri Laurie L   Ait-Daoud Nassima N   Johnson Bankole A BA   Ransom Janet J   Scott Charles C   Koob George F GF   Litten Raye Z RZ  

Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20160923 5


Alcohol use disorder has been linked to dysregulation of the brain stress systems, producing a negative emotional state leading to chronic relapsing behavior. Vasopressin receptors appear to have a regulatory role in stress, anxiety, and alcohol. This study evaluated the novel compound, ABT-436, a V1b receptor antagonist, in alcohol-dependent participants in a 12-week clinical trial. Men and women (n=150) who met criteria for DSM-IV alcohol dependence were recruited across four sites. Participan  ...[more]

Similar Datasets

| S-EPMC3914416 | biostudies-literature
| S-EPMC7493392 | biostudies-literature
| S-EPMC3162484 | biostudies-literature
| S-EPMC8406061 | biostudies-literature
| S-EPMC6317996 | biostudies-literature
| S-EPMC3355217 | biostudies-literature
| S-EPMC4122522 | biostudies-literature
| S-EPMC3602333 | biostudies-literature
| S-EPMC3154755 | biostudies-literature
| S-EPMC2875545 | biostudies-literature